{
    "clinical_study": {
        "@rank": "101017", 
        "acronym": "Rev-EHPAD", 
        "arm_group": {
            "arm_group_label": "The study population", 
            "arm_group_type": "Other", 
            "description": "See inclusion and exclusion criteria.\nIntervention: Before-after study"
        }, 
        "brief_summary": {
            "textblock": "The main objective of the study is to show that the multidisciplinary review of drug\n      prescriptions changes the adverse drug event (ADE) geriatric risk score (according to\n      Trivalle and Ducimeti\u00e8re 2013) for patients living in the N\u00eemes University Hospital\n      Residence for Dependent Elderly."
        }, 
        "brief_title": "Impact of Multidisciplinary Review of Drug Prescriptions on Patient Safety in a Residence for Dependent Elderly", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Geriatrics", 
            "Residence for Dependent Elderly", 
            "Health Services for the Aged"
        ], 
        "detailed_description": {
            "textblock": "The secondary objectives of this study are to assess and compare the following criteria\n      before and after multidisciplinary review of drug prescriptions for patients in the N\u00eemes\n      University Hospital Residence for Dependent Elderly:\n\n      A. the number of patients with at least one potentially inappropriate drug prescribed\n\n      B. the number of hospitalizations\n\n      C. death rate\n\n      D. the number of falls per patient and the rate of fallers\n\n      E. qualitative criteria describing the drug review\n\n      F. associated care costs"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient (or his/her legal representative) must have given his/her informed and\n             signed consent\n\n          -  The patient must be insured or beneficiary of a health insurance plan\n\n          -  The patient is available for 6 months of follow-up\n\n          -  The patient has resided at the N\u00eemes University Hospital Residence for Dependent\n             Elderly for at least the past 6 months\n\n        Exclusion Criteria:\n\n          -  The patient is participating in another study\n\n          -  The patient is in an exclusion period determined by a previous study\n\n          -  The patient is under judicial protection\n\n          -  The patient (or his/her legal representative) refuses to sign the consent\n\n          -  It is impossible to correctly inform the patient (or his/her legal representative)\n\n          -  The patient has resided at the N\u00eemes University Hospital Residence for Dependent\n             Elderly for less than 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118259", 
            "org_study_id": "LOCAL/2013/GL-01", 
            "secondary_id": "2013-A01590-45"
        }, 
        "intervention": {
            "arm_group_label": "The study population", 
            "description": "The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.\nThe first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.\nThe proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.\nDuring the second observational phase, the same data as in the first observational phase will be collected a second time.", 
            "intervention_name": "Before-after study", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multidisciplinary review of drug prescriptions", 
            "Adverse drug events geriatric risk score", 
            "Residence for dependent elderly"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "N\u00eemes", 
                        "country": "France", 
                        "zip": "30029"
                    }, 
                    "name": "CHRU de N\u00eemes - Centre de G\u00e9rontologie de Serre Cavalier"
                }, 
                "investigator": {
                    "last_name": "Sabine Rouvi\u00e8re, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "N\u00eemes Cedex 09", 
                        "country": "France", 
                        "zip": "30029"
                    }, 
                    "name": "CHRU de N\u00eemes - H\u00f4pital Universitaire Car\u00e9meau"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Impact of Multidisciplinary Review of Drug Prescriptions on Patient Safety in a Residence for Dependent Elderly", 
        "overall_contact": {
            "email": "geraldine.leguelinel@chu-nimes.fr", 
            "last_name": "G\u00e9raldine Leguelinel, Pharm-D", 
            "phone": "+33.(0)4.66.68.38.44"
        }, 
        "overall_contact_backup": {
            "email": "carey.suehs@chu-nimes.fr", 
            "last_name": "Carey M Suehs, PhD", 
            "phone": "+33.(0)4.66.68.67.88"
        }, 
        "overall_official": {
            "affiliation": "Centre Hospitalier Universitaire de N\u00eemes", 
            "last_name": "G\u00e9raldine Leguelinel, Pharm-D", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "according to Trivalle and Ducimeti\u00e8re 2013", 
            "measure": "Adverse Drug Events Geriatric Risk Score", 
            "safety_issue": "Yes", 
            "time_frame": "change from Baseline to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118259"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Laroche et al 2007.", 
                "measure": "The number of patients taking at least 1 potentially inappropriate drug according to Laroche criteria", 
                "safety_issue": "Yes", 
                "time_frame": "During the proactive phase. Day 0."
            }, 
            {
                "measure": "Number of hospitalizations in the public sector (higher level care)", 
                "safety_issue": "Yes", 
                "time_frame": "first observational phase (month -6 to day 0)"
            }, 
            {
                "measure": "Number of hospitalizations in the public sector (higher level care)", 
                "safety_issue": "Yes", 
                "time_frame": "second observational phase (day 0 to month 6)"
            }, 
            {
                "measure": "Days of hospitalization in the public sector (higher level care)", 
                "safety_issue": "Yes", 
                "time_frame": "first observational phase (month -6 to day 0)"
            }, 
            {
                "measure": "Days of hospitalization in the public sector (higher level care)", 
                "safety_issue": "Yes", 
                "time_frame": "second observational phase (day 0 to month 6)"
            }, 
            {
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "first observational phase (month -6 to day 0)"
            }, 
            {
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "second observational phase (day 0 to month 6)"
            }, 
            {
                "measure": "The number of falls per patient", 
                "safety_issue": "Yes", 
                "time_frame": "first observational phase (month -6 to day 0)"
            }, 
            {
                "measure": "The number of falls per patient", 
                "safety_issue": "Yes", 
                "time_frame": "second observational phase (day 0 to month 6)"
            }, 
            {
                "measure": "The percentage of patients who fell", 
                "safety_issue": "Yes", 
                "time_frame": "first observational phase (month -6 to day 0)"
            }, 
            {
                "measure": "The percentage of patients who fell", 
                "safety_issue": "Yes", 
                "time_frame": "second observational phase (day 0 to month 6)"
            }, 
            {
                "measure": "The Anatomical Therapeutic Chemical classification for each revised drug", 
                "safety_issue": "No", 
                "time_frame": "during the proactive phase (day 0)"
            }, 
            {
                "description": "Contra-indication, dosing, route, etc", 
                "measure": "The type of errors detected during drug review", 
                "safety_issue": "Yes", 
                "time_frame": "during the proactive phase (day 0)"
            }, 
            {
                "description": "discontinuation, addition, substitution...", 
                "measure": "The type of modification suggested during drug review", 
                "safety_issue": "Yes", 
                "time_frame": "during the proactive phase (day 0)"
            }, 
            {
                "measure": "The acceptation rate for modifications suggested during drug review", 
                "safety_issue": "Yes", 
                "time_frame": "during the proactive phase (day 0)"
            }, 
            {
                "measure": "Associated care costs (\u20ac)", 
                "safety_issue": "Yes", 
                "time_frame": "first observational phase (month -6 to day 0)"
            }, 
            {
                "measure": "Associated care costs (\u20ac)", 
                "safety_issue": "Yes", 
                "time_frame": "second observational phase (day 0 to month 6)"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de N\u012bmes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de N\u012bmes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}